• Je něco špatně v tomto záznamu ?

Hypericin affects cancer side populations via competitive inhibition of BCRP

J. Vargová, J. Mikeš, R. Jendželovský, L. Mikešová, B. Kuchárová, Ľ. Čulka, R. Fedr, J. Remšík, K. Souček, A. Kozubík, P. Fedoročko,

. 2018 ; 99 (-) : 511-522. [pub] 20180220

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033150

OBJECTIVE: Cancer stem-like cells (CSLCs) are considered a root of tumorigenicity and resistance. However, their identification remains challenging. The use of the side population (SP) assay as a credible marker of CSLCs remains controversial. The SP assay relies on the elevated activity of ABC transporters that, in turn, can be modulated by hypericin (HYP), a photosensitizer and bioactive compound of St. John's Wort (Hypericum perforatum), a popular over-the-counter antidepressant. Here we aimed to comprehensively characterize the SP phenotype of cancer cells and to determine the impact of HYP on these cells. METHODS: Flow cytometry and sorting-based assays were employed, including CD24-, CD44-, CD133-, and ALDH-positivity, clonogenicity, 3D-forming ability, ABC transporter expression and activity, and intracellular accumulation of HYP/Hoechst 33342. The tumorigenic ability of SP, nonSP, and HYP-treated cells was verified by xenotransplantation into immunodeficient mice. RESULTS: The SP phenotype was associated with elevated expression of several investigated transporters and more intensive growth in non-adherent conditions but not with higher clonogenicity, tumorigenicity or ALDH-positivity. Despite stimulated BCRP level and MRP1 activity, HYP reversibly decreased the SP proportion, presumably via competitive inhibition of BCRP. HYP-selected SP cells acquired additional traits of resistance and extensively eliminated HYP. CONCLUSIONS: Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033150
003      
CZ-PrNML
005      
20181009110809.0
007      
ta
008      
181008s2018 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2018.01.074 $2 doi
035    __
$a (PubMed)29665654
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Vargová, Jana $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
245    10
$a Hypericin affects cancer side populations via competitive inhibition of BCRP / $c J. Vargová, J. Mikeš, R. Jendželovský, L. Mikešová, B. Kuchárová, Ľ. Čulka, R. Fedr, J. Remšík, K. Souček, A. Kozubík, P. Fedoročko,
520    9_
$a OBJECTIVE: Cancer stem-like cells (CSLCs) are considered a root of tumorigenicity and resistance. However, their identification remains challenging. The use of the side population (SP) assay as a credible marker of CSLCs remains controversial. The SP assay relies on the elevated activity of ABC transporters that, in turn, can be modulated by hypericin (HYP), a photosensitizer and bioactive compound of St. John's Wort (Hypericum perforatum), a popular over-the-counter antidepressant. Here we aimed to comprehensively characterize the SP phenotype of cancer cells and to determine the impact of HYP on these cells. METHODS: Flow cytometry and sorting-based assays were employed, including CD24-, CD44-, CD133-, and ALDH-positivity, clonogenicity, 3D-forming ability, ABC transporter expression and activity, and intracellular accumulation of HYP/Hoechst 33342. The tumorigenic ability of SP, nonSP, and HYP-treated cells was verified by xenotransplantation into immunodeficient mice. RESULTS: The SP phenotype was associated with elevated expression of several investigated transporters and more intensive growth in non-adherent conditions but not with higher clonogenicity, tumorigenicity or ALDH-positivity. Despite stimulated BCRP level and MRP1 activity, HYP reversibly decreased the SP proportion, presumably via competitive inhibition of BCRP. HYP-selected SP cells acquired additional traits of resistance and extensively eliminated HYP. CONCLUSIONS: Our results suggest that SP is not an unequivocal CSLC-marker. However, SP could play an important role in modulating HYP-treatment and serve as a negative predictive tool for HYP-based therapies. Moreover, the use of supplements containing HYP by cancer patients should be carefully considered, due to its proposed effect on drug efflux and complex impact on tumor cells, which have not yet been sufficiently characterized.
650    _2
$a ABC transportér z rodiny G, člen 2 $x metabolismus $7 D000070997
650    _2
$a P-glykoprotein $x metabolismus $7 D020168
650    _2
$a aldehyddehydrogenasa $x metabolismus $7 D000444
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a karcinogeneze $x účinky léků $x metabolismus $x patologie $7 D063646
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a buněčné klony $7 D002999
650    _2
$a lidé $7 D006801
650    _2
$a myši SCID $7 D016513
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a nádory $x metabolismus $x patologie $7 D009369
650    _2
$a nádorové kmenové buňky $x účinky léků $x metabolismus $x patologie $7 D014411
650    _2
$a perylen $x analogy a deriváty $x farmakologie $7 D010569
650    _2
$a fenotyp $7 D010641
650    _2
$a vedlejší populace buněk $x účinky léků $x patologie $7 D058985
650    _2
$a buněčné sféroidy $x účinky léků $x metabolismus $x patologie $7 D018874
650    _2
$a substrátová specifita $x účinky léků $7 D013379
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mikeš, Jaromír $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
700    1_
$a Jendželovský, Rastislav $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
700    1_
$a Mikešová, Lucia $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
700    1_
$a Kuchárová, Barbora $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
700    1_
$a Čulka, Ľubomír $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic.
700    1_
$a Fedr, Radek $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91, Brno, Czech Republic.
700    1_
$a Remšík, Ján $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
700    1_
$a Souček, Karel $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
700    1_
$a Kozubík, Alois $u Institute of Biophysics of the Czech Academy of Sciences, Brno, Královopolská 135, 612 65, Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic.
700    1_
$a Fedoročko, Peter $u Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54, Košice, Slovak Republic. Electronic address: peter.fedorocko@upjs.sk.
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 99, č. - (2018), s. 511-522
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29665654 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181009111257 $b ABA008
999    __
$a ok $b bmc $g 1340029 $s 1030144
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 99 $c - $d 511-522 $e 20180220 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...